BriaCell Therapeutics rises on preparatory work for breast cancer therapy trial
07/04/2022 15:07
** Shares of drug developer BCTX.O rise ~2% to $10.94
** Co says immunotherapy candidate, Bria-OTS, is currently
being manufactured and undergoing quality control testing ahead
of upcoming clinical trial urn:newsml:reuters.com:*:nFWN2W50J6
** BriaCell expects Bria-OTS to enter early-to-mid-stage
trial in patients with advanced breast cancer
** BriaCell and National Cancer Institute collaborating on
Bria-OTS, which is an off-the-shelf personalized immunotherapy
** Bria-OTS is believed to activate patient's immune system
to recognize and eliminate cancerous cells, by both activating
tumor-directed T cells and antibody responses
** Stock up 31.91% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study